Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications
Introduction. The tactics of managing and treating patients with chronic recurrent bacterial prostatitis (CRBP) in some cases is a difficult-to-treat condition for a practicing urologist. This circumstance occurs because the disease has several predisposing factors, a complex and multifaceted pathog...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation
2023-01-01
|
| Series: | Vestnik Urologii |
| Subjects: | |
| Online Access: | https://www.urovest.ru/jour/article/view/623 |
| _version_ | 1797272088595136512 |
|---|---|
| author | Kh. S. Ibishev Yu. L. Naboka P. A. Krainiy I. A. Gudima A. D. Plyakin J. O. Prokop A. V. Ilyash |
| author_facet | Kh. S. Ibishev Yu. L. Naboka P. A. Krainiy I. A. Gudima A. D. Plyakin J. O. Prokop A. V. Ilyash |
| author_sort | Kh. S. Ibishev |
| collection | DOAJ |
| description | Introduction. The tactics of managing and treating patients with chronic recurrent bacterial prostatitis (CRBP) in some cases is a difficult-to-treat condition for a practicing urologist. This circumstance occurs because the disease has several predisposing factors, a complex and multifaceted pathogenesis, and certain difficulties in diagnosis and treatment.Objective. To study the effectiveness of recombinant interferon α-2b medications in post-COVID-19 patients with chronic recurrent prostatitis against the background of antibiotic multi-drug resistance of microorganisms verified in prostate secretion.Materials and methods. The treatment of 52 post-COVID-19 patients with CRBP was analyzed, divided into three therapy-dependent groups. Group 1 patients (n = 18) received antibiotic therapy (ABT): Levofloxacin 500 mg q.d. PO for 28 days. Group 2 patients (n = 18) underwent combined therapy: ABT supplemented with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (“Viferon®” rectal suppositories) 3.000.000 IU b.i.d. PR q12h for 28 days. Group 3 patients (n = 16) received monotherapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (“Viferon®”rectal suppositories) 3.000.000 IU b.i.d. PR q12h for 28 days. The follow-up period was 6 months with monitoring of clinical and laboratory parameters assessed before treatment, after 1, 3 and 6 months from the start of therapy.Results. Based on the monitoring of the clinical picture and laboratory parameters, after 1 follow-up month, there was a significant decrease in the symptoms of the disease in all study groups. However, after 3 and 6 follow-up months, this trend was observed only in patients of groups 2 and 3 receiving recombinant interferon alfa-2b with an antioxidant complex (vitamins E and C).Conclusions. Strengthening the standard CRBP-therapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C makes it possible to normalize both clinical and laboratory parameters in most patients. |
| first_indexed | 2024-03-07T14:23:24Z |
| format | Article |
| id | doaj.art-98ed3d737f0241c3890bc838b8935d62 |
| institution | Directory Open Access Journal |
| issn | 2308-6424 |
| language | Russian |
| last_indexed | 2024-03-07T14:23:24Z |
| publishDate | 2023-01-01 |
| publisher | State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation |
| record_format | Article |
| series | Vestnik Urologii |
| spelling | doaj.art-98ed3d737f0241c3890bc838b8935d622024-03-06T08:56:06ZrusState Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian FederationVestnik Urologii2308-64242023-01-01104324210.21886/2308-6424-2022-10-4-32-42407Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medicationsKh. S. Ibishev0Yu. L. Naboka1P. A. Krainiy2I. A. Gudima3A. D. Plyakin4J. O. Prokop5A. V. Ilyash6Rostov State Medical UniversityRostov State Medical UniversityMedical Center «Professional», Ltd.Rostov State Medical UniversityLenin Shakhty City Emergency HospitalRostov State Medical UniversityRostov State Medical UniversityIntroduction. The tactics of managing and treating patients with chronic recurrent bacterial prostatitis (CRBP) in some cases is a difficult-to-treat condition for a practicing urologist. This circumstance occurs because the disease has several predisposing factors, a complex and multifaceted pathogenesis, and certain difficulties in diagnosis and treatment.Objective. To study the effectiveness of recombinant interferon α-2b medications in post-COVID-19 patients with chronic recurrent prostatitis against the background of antibiotic multi-drug resistance of microorganisms verified in prostate secretion.Materials and methods. The treatment of 52 post-COVID-19 patients with CRBP was analyzed, divided into three therapy-dependent groups. Group 1 patients (n = 18) received antibiotic therapy (ABT): Levofloxacin 500 mg q.d. PO for 28 days. Group 2 patients (n = 18) underwent combined therapy: ABT supplemented with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (“Viferon®” rectal suppositories) 3.000.000 IU b.i.d. PR q12h for 28 days. Group 3 patients (n = 16) received monotherapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (“Viferon®”rectal suppositories) 3.000.000 IU b.i.d. PR q12h for 28 days. The follow-up period was 6 months with monitoring of clinical and laboratory parameters assessed before treatment, after 1, 3 and 6 months from the start of therapy.Results. Based on the monitoring of the clinical picture and laboratory parameters, after 1 follow-up month, there was a significant decrease in the symptoms of the disease in all study groups. However, after 3 and 6 follow-up months, this trend was observed only in patients of groups 2 and 3 receiving recombinant interferon alfa-2b with an antioxidant complex (vitamins E and C).Conclusions. Strengthening the standard CRBP-therapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C makes it possible to normalize both clinical and laboratory parameters in most patients.https://www.urovest.ru/jour/article/view/623chronic bacterial prostatitisprostate secretioncytokinesimmunotherapyinterferons |
| spellingShingle | Kh. S. Ibishev Yu. L. Naboka P. A. Krainiy I. A. Gudima A. D. Plyakin J. O. Prokop A. V. Ilyash Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications Vestnik Urologii chronic bacterial prostatitis prostate secretion cytokines immunotherapy interferons |
| title | Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications |
| title_full | Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications |
| title_fullStr | Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications |
| title_full_unstemmed | Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications |
| title_short | Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications |
| title_sort | treatment of post covid 19 patients with chronic recurrent prostatitis efficacy of recombinant interferon α 2b medications |
| topic | chronic bacterial prostatitis prostate secretion cytokines immunotherapy interferons |
| url | https://www.urovest.ru/jour/article/view/623 |
| work_keys_str_mv | AT khsibishev treatmentofpostcovid19patientswithchronicrecurrentprostatitisefficacyofrecombinantinterferona2bmedications AT yulnaboka treatmentofpostcovid19patientswithchronicrecurrentprostatitisefficacyofrecombinantinterferona2bmedications AT pakrainiy treatmentofpostcovid19patientswithchronicrecurrentprostatitisefficacyofrecombinantinterferona2bmedications AT iagudima treatmentofpostcovid19patientswithchronicrecurrentprostatitisefficacyofrecombinantinterferona2bmedications AT adplyakin treatmentofpostcovid19patientswithchronicrecurrentprostatitisefficacyofrecombinantinterferona2bmedications AT joprokop treatmentofpostcovid19patientswithchronicrecurrentprostatitisefficacyofrecombinantinterferona2bmedications AT avilyash treatmentofpostcovid19patientswithchronicrecurrentprostatitisefficacyofrecombinantinterferona2bmedications |